When patient recruitment slows, the risk of study delays and costly rework rises sharply. For one sponsor struggling to meet sample size targets, MMS leveraged KerusCloud®, a simulation-driven study design platform, to explore adaptive solutions that maintained trial validity and regulatory confidence.

Through rapid, data-based scenario modeling, MMS evaluated interim analysis options, stopping rules, and statistical trade-offs helping the sponsor make an informed, confident decision while maintaining study power and reducing operational risk.

This case study highlights how KerusCloud® simulations enable adaptive flexibility, guiding sponsors to smarter study designs that save time, reduce uncertainty, and ensure every patient counts.

Key Benefits / What You’ll Learn:

• Evaluate adaptive trial options using virtual simulations before making design changes.
• Quantify risk and probability of success (PoS) for different sample size and interim analysis scenarios.
• Optimize recruitment efficiency without compromising data integrity or alpha control.
• Enable faster, evidence-based decision-making during live studies.
• Maintain regulatory confidence through transparent, simulation-supported justifications.

Developed by MMS statistical experts, KerusCloud® empowers global sponsors to confidently adapt trial strategies while maintaining scientific rigor — trusted by leading biopharma and regulators worldwide.